Researchers are analyzing gene expression signatures to better predict which therapy will work best for each patient with cancer.
Potential Target Identified for Treating Chemotherapy-Associated Kidney Damage
Recent findings that the protein molecule APE2 is implicated in cisplatin-related toxicity will be extended through new research grant funding aimed at pharmacologic interventions.
Neurocognitive Deficits Prevalent in Patients With Hearing Loss Caused by Cancer Treatment
The use of sodium thiosulfate to prevent hearing loss in children treated with cisplatin appears promising, according to recent studies, but more research is needed. Pediatric oncologist Stefanie Thomas, MD, MS, explains.
Chemo Plus Immunotherapy Shows Promise for Advanced Bladder Cancer
The combination of nivolumab, gemcitabine and cisplatin produces significant pathologic response rates in patients with muscle-invasive bladder cancer (MIBC) in the neoadjuvant setting, according to new data from the phase II Bladder Cancer Signal Seeking Trial.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
These Are the ASCO 2019 Abstracts That Will Make a Difference
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
Optimal Total Dose of Cisplatin for High-Risk Oral Cavity Squamous Cell Carcinoma
In high-risk resected oral cavity squamous cell carcinoma, median disease-free survival doubles when patients receive 200 mg/m2 or more of cisplatin along with radiation therapy, shows one study.
Cisplatin + Experimental Drug Highly Effective Against Small Cell Lung Cancer
Cisplatin and CBL0137 work synergistically to attack a combination of three different cellular pathways that contribute to chemotherapy resistance.